Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen’s Melanoma Vaccine Shows Durable Response; Survival Still A Hurdle

This article was originally published in The Pink Sheet Daily

Executive Summary

The vaccine acquired from BioVex at high cost still needs to demonstrate overall survival in Phase III and prove value in an increasingly competitive market for melanoma treatments.

Advertisement

Related Content

Amgen’s Trebananib Meets First Phase III Goal In Ovarian Cancer
Amgen’s Trebananib Meets First Phase III Goal In Ovarian Cancer
Yervoy Approval Has Shifted Development Landscape For Melanoma
Amgen Takes Out Cancer Vaccine Developer BioVex In Potential $1B Deal

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS075420

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel